About 21 results found for searched term "GSK-25" (0.098 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1728 | GSK256066 | PDE |
| GSK256066 is a selective phosphodiesterase 4 (PDE4)inhibitor with an IC50 of 3.2 pM. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M2190 | I-BET-762 | Epigenetic Reader Domain |
| GSK525762 | ||
| I-BET-762 (GSK525762) is a selective small molecule BET inhibitor. | ||
| M4831 | GSK2578215A | LRRK2 |
| GSK2578215A is a potent and selective LRRK2 kinase inhibitor with IC50 of 8.9 nM and 10.9 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively. | ||
| M4954 | EPZ015666 | PRMTs |
| GSK3235025 | ||
| EPZ015666 is a potent, selective and orally bioavailable PRMT5 inhibitor with Ki of 5 nM, >20,000-fold selectivity over other PMTs. | ||
| M5210 | GSK1325756 (Danirixin) | CXCR |
| Danirixin | ||
| GSK1325756 (Danirixin) is a non-peptide, high affinity, selective and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8. | ||
| M6139 | GSK2256098 | FAK |
| GTPL7939 | ||
| GSK2256098 is a potent, selective, reversible, and ATP competitive FAK kinase inhibitor with apparent Ki of 0.4 nM. | ||
| M7551 | Solcitinib | JAK |
| GSK-2586184; GLPG-0778 | ||
| Solcitinib is an oral, competitive, potent, and selective JAK1 inhibitor with an IC50 value of 9.8 nM, which is 11,55, and 23 times more selective than JAK2, JAK3, and TYK2. Solcitinib can be used in studies of psoriasis. | ||
| M10715 | GSK189254A | Histamine Receptor |
| GSK189254 | ||
| GSK189254A (GSK189254) is a novel and highly effective selective H3 receptor antagonist for H3 in humans and ratshpi | ||
| M11467 | GSK-2250665A | Itk |
| GSK2250665; GSK-2250665 | ||
| GSK-2250665A is a Itk inhibitor with pKi value of 9.2. | ||
| M13394 | GSK2593074A | RIPK |
| GSK'074 | ||
| GSK2593074A is a necroptosis inhibitor that inhibits RIP1 and 3. | ||
| M13825 | Molibresib besylate | Epigenetic Reader Domain |
| GSK 525762C; I-BET 762 besylate | ||
| Molibresib besylate (GSK 525762C; I-BET 762 besylate) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM. | ||
| M14423 | GSK2256294A | Epoxide Hydrolase |
| GSK 2256294 | ||
| GSK2256294A is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH. | ||
| M14503 | GSK256066 Trifluoroacetate | PDE |
| GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease. | ||
| M14712 | GSK 525768A | Others |
| GSK 525768A is the inactive enantiomer of GSK525762A. GSK 525768A has no activity towards BET. | ||
| M21061 | GSK3640254 | Others |
| GSK3640254 is an HIV maturation inhibitor and Phase IIb clinical candidate (60-180 mg PO QD) active against a range of HIV strains with the Gag polymorphism. | ||
| M25135 | Alunacedase alfa | Anti-infection |
| HrsACE2; GSK 2586881 | ||
| Alunacedase alfa (HrsACE2; GSK 2586881) is a human recombinant soluble angiotensin-converting enzyme-2 (hrsACE2). Alunacedase alfa is a genetically modified soluble form of ACE2, it decreases cell entry of SARS-CoV-2 competing for membrane-bound ACE2. Alunacedase alfa has the potential for the research of SARS-CoV-2. | ||
| M25395 | GSK1379725A | Epigenetic Reader Domain |
| AU1; AU-1 | ||
| GSK1379725A (AU1) is the first selective BPTF (Bromodomain PHD Finger Transcription Factor) ligand with a Kd of 2.8 uM, showing no binding activity for Brd4. | ||
| M29271 | GSK251 | PI3K |
| GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of PI3Kδ with a novel binding mode. | ||
| M41950 | GSK 1562590 hydrochloride | Others |
| GSK 1562590 hydrochloride is a high affinity and selective antagonist of urotensin-II receptor (UT), with pKis of 9.14-9.66 for mammalian recombinant (mouse, rat, cat, monkey, human) and native UT. | ||
| M45123 | GSK256073 | GPR/FFAR |
| GSK256073 is a potent, selective, orally active GPR109A agonist and a potent and persistent HCA2 agonist with a pEC50 of 7.5 (Human HCA2). In addition, GSK256073 significantly improves glucose homeostasis by inhibiting lipid degradation and has potential for the study of type 2 diabetes mellitus (T2DM) and dyslipidemia. | ||
| M49532 | GSK-25 | ROCK |
| GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
